Procarbazin in advanced malignant melanoma.
Experience in applying procarbazin in the treatment of advanced malignant melanoma are very limited. Actually it has never been adequately tested as monotherapy. We administered procarbazin to 28 patients in a dosis of 100 mg/m2 on days 1 to 10 at 4-week intervals. As a result we obtained 25% remissions which suggest that procarbazin deserves greater attention in the above indication.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use*
D011344:Procarbazine